Liraglutide was also associated with a reduction in mean ALT levels, which, however, disappeared after correction for changes in weight and HbA 1c (62, 63)
Ozempic, or semaglutide, is just one drug in a growing class of medications known as GLP-1 agonists
For diabetes-specific data, the completed TRANSCEND-T2D-1 trial (537 patients, 40 weeks) is the relevant source: retatrutide reduced HbA1c by up to 2.0% (9mg dose), with 8289% of patients reaching the 120 bpm at rest) The Unknowns: What We're Still Waiting to Learn Full 2-year published safety data: TRIUMPH-1 104-week extension data is available for the BMI 35 subgroup, but full publication of the complete 2-year dataset is pending expected late 2026
The regulatory framework for compounded pharmaceuticals does not extend to investigational research peptides, and a vendor association with compounding does not guarantee research peptide quality